Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advaxis Sinks On Delayed Disclosure Of Clinical Hold

This article was originally published in Scrip

Executive Summary

Advaxis Inc. fell 25.8% in after-hours trading on Oct. 6 when the company said the US FDA placed a clinical hold on its investigational new drug (IND) application for axalimogene filolisbac (ADXS-HPV) – a disclosure that was made five days after Advaxis received word from the agency.

You may also be interested in...



Ports, Prosthetics Take Blame In Partial Hold For Aduro’s Immunotherapy Trials

Aduro hopes for a relatively quick resolution to a clinical hold for its LADD cancer vaccine studies instituted by the FDA based on listeria detected around indwelling ports in two patients.

Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost

Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.

Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up

Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029974

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel